Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The brand has added a range of exciting new products especially formulated for oily skin.
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Dr. Raman has succeeded Victoria Richon
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Subscribe To Our Newsletter & Stay Updated
